Persistence buys 16% stake in Warnex

Persistence Capital Partners LP has acquired privately about 10.7 million common shares, or a 16% interest in Warnex (TSX:WNX), and $1.5 million of Warnex convertible debentures from SGF Soquia Inc. for investment purposes. Financial details weren’t disclosed but assuming conversion of the debentures, Persistence would hold about 19% of Warnex’s common shares. “We are excited [...]

Warnex in group to develop new diagnostic test

Warnex (TSX:WNX), the Montreal Heart Institute and the Centre of Excellence in Personalized Medicine are collaborating to develop a new diagnostic test for early detection of cardiovascular and metabolic diseases to enable more personalized treatment of diseases such as atherosclerosis and diabetes. The test will be developed by Warnex in collaboration with Dr. Eric Thorin, [...]

Medical Lab division to drive Warnex

After obtaining rights to a colorectal cancer blood screening test in May, Warnex (TSX:WNX) is looking for additional products to license into its Medical Laboratories division as it seeks to become the “unique provider” of specialized diagnostic tests in Canada. “Our other divisions are coming out of the recession okay, and we getting busy.  But [...]